SARM1 inhibitors, having demonstrated the ability to prevent axonal degeneration, are being evaluated for the treatment of a number of neurodegenerative disorders. Once approved, these therapies are likely to capture a significant market share
announced the addition of “SARM1 Inhibitors Therapeutics Market,
2022 – 2040”
report to its list of offerings.
Presently, several industry and
non-industry stakeholders are evaluating SARM1 inhibitors as potential therapeutic agents for the treatment
of neurological disorders across various
preclinical studies and early stages of clinical development, worldwide. With
the ongoing pace of innovation in this field, increasing R&D activity and
promising pre-clinical data, several promising leads are anticipated to be
commercially launched over the coming decade and SARM1 targeting therapeutics
market is anticipated to witness substantial growth in the mid to long-term.
Key Market Insights
several SARM1 targeting therapy candidates are being developed by various
65% of the pipeline candidates are currently being evaluated in the preclinical
stages of development, followed by those currently in the discovery stage
(35%). Further, it is worth mentioning that close to 85% of the SARM1
inhibitors are small molecules.
a number of companies claim to be engaged in the development of SARM1
SARM1 inhibitors market is dominated by the presence of
large companies (81%), followed by small players (19%). In addition, around 20%
of the players were established post-2010.
articles related to SARM1 inhibitors have been published between 2011 and 2022
(81%) of the articles published in this domain were research papers, followed
by review papers (12%). It is important to note that more than 70% of the total
number of articles were published post-2018.
30 grants have been awarded for research related to SARM1 inhibitors, since
to 40% of the total amount was awarded under the R01 mechanism (which
supports research projects). Further, genetics and neurology emerged as the
key research departments, having received 34% of the total grants, each.
patents related to SARM1 targeting therapeutics have been filed / granted till
the years, the number of patents filed for SARM1 inhibitors has increased
gradually; majority of the patents have been filed / granted in 2021. Most of
the patents in this domain are patent applications (96%), followed by granted
America is anticipated to capture more than 65% share of the market, by 2040
2040, the market revenues are likely to be driven by the sales of small
molecules (95%) being developed as SARM1 inhibitors. Further, sales of
therapeutics targeting multiple sclerosis are likely to contribute to a
majority share (~40%) of revenues, in the long term.
To request a sample copy / brochure of this report,
§ Who are
the leading players engaged in the development of SARM1 targeting therapeutics?
§ What is
the evolving trend of publications focused on SARM1 targeting therapeutics?
§ How is the
intellectual property landscape in this field likely to evolve in the foreseen
§ What are
the recent developments and strategic initiatives undertaken by players engaged
in this market space related to the research and development of SARM1 targeting
§ What are
the key value drivers that are likely to influence the evolution of this
§ How is the
current and future market opportunity likely to be distributed across key
financial opportunity within the SARM1 targeting therapeutics market has been
analyzed across the following segments:
Central and Ocular Nervous System Disorders
The research includes detailed
profiles of key players (listed below); featuring an overview of the company,
financial information (if available), details related to its product
portfolio, patent portfolio, recent developments (including partnerships and
collaborations) and an informed future outlook.
§ Disarm Therapeutics
§ Nura Bio
§ Washington University
For additional details, please
or email firstname.lastname@example.org
You may also be interested in the following
1. RNAi Market: Therapeutics and Technologies
(Focus on siRNA, miRNA, shRNA and DNA) (3rd Edition): Industry Trends and Global Forecasts, 2022-2035
2. Global Therapeutic Vaccines Market: Industry Trends and Global Forecasts,
About Roots Analysis
Roots Analysis is a
global leader in the pharma / biotech market research. Having worked with over
750 clients worldwide, including Fortune 500 companies, start-ups, academia,
venture capitalists and strategic investors for more than a decade, we offer a
highly analytical / data-driven perspective to a network of over 450,000 senior
industry stakeholders looking for credible market insights.
+1 (415) 800 3415